Saint Petersburg, FL, May 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Apotheca Biosciences (OTC PINK: CBDC), a developer of cutting-edge medical & pharmaceutical products, nutraceuticals, and cannabis delivery technologies for the health care and consumer care industry, is pleased to announce that its product line under its ProMED subsidiary and brand has received great response from customers around the country. ProMED product line can be found here;
At ProMED CBD, our focus is to research and develop innovative CBD hemp extracts and to make them accessible worldwide. Our team, made up of doctors and scientists, is dedicated to producing the finest and purest CBD products while never compromising on quality. ProMED uses whole-plant hemp extracts which are either full-spectrum (i.e. CBD and a natural balance of cannabinoids, flavonoids, and terpenes) or isolated Crystalline Cannabinoid CBD.
Through our efforts in research and development, our primary goal is to create diverse, high-quality hemp extracts with a broad profile of cannabinoids and other natural molecules found in hemp, while identifying their distinct properties for future FDA fast track. Unlike other CBD retailers, ProMED, through its pharmaceutical division run by Apotheca Biosciences, will develop and manufacture treatment based OTC formulations for common illnesses using cannabinoids, flavonoids, terpenes and other APIs.
ProMED Biosciences is shipping their newest flag-ship pharma grade CBD product line under the trademarked brand name ProMED. ProMED Biosciences carries cannabidiol (CBD) related products, from tinctures to cosmetics, which are distributed nationally in wellbeing centers, dispensaries, spas, health food stores, vitamin shops, health care providers, online and through distributors. Company expects substantial revenue potential from ProMED subsidiary.
For immediate white-label and wholesale distribution & pricing please contact info@promedcbd.com.
ProMED will initially carry 13 product SKUs which includes:
- 500 mg 30 ml CBD Oil Drops (Isolate)
- 500 mg 30 ml CBD Oil Drops (Full Spectrum)
- 1000 mg 30 ml CBD Tincture (Isolate)
- 1000 mg 30 ml CBD Tincture (Full Spectrum)
- Crystal Resistant Broad Spectrum Vape Juices in 1000 & 1500 mg
- Full Spectrum Vape Juices in 1000 & 1500 mg
- 250 mg 3.4oz Air Pump Pain Cream (Isolate)
- 250 mg 3.4oz Air Pump Pain Cream (Full Spectrum)
- 25 mg Soft Gel Capsule 30 count bottle (Isolate)
- 25 mg Soft Gel Capsule 30 count bottle (Full Spectrum)
- 25 mg Dry Cap Sleep Aid 30 count bottle (Isolate)
- 500 mg OTC Sport Pain Cream (Isolate)
- 320 mg OTC Sport Pain Balm Stick (Isolate)
Full Traceability and Transparency
Our products are carefully developed and formulated from proprietary strains of hemp that have been derived from fully traceable USDA registered industrial hemp farms with full ISO and GMP-compliant traceability reports and COAs. Products have been and may be formulated and manufactured in an FDA registered, ISO 9001-22716, cGMP and OTC certified facilities.
Apotheca Biosciences is a pioneering biotech company with an emphasis in research and development in addition to the creation of high-grade nutraceuticals and cosmetics. The health of our customers takes precedence and our solid business strategy ensures focus on customer well-being. Our goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects our strategy and research. For more information on Apotheca Biosciences, please visit www.apothecabiosciences.com and https://promedcbd.com.
About ProMED Biosciences Inc. – Science Based Well Being
ProMED Biosciences is a developer and manufacturer of medical grade CBD and cannabinoids products that enhances wellbeing and quality of life. ProMED is and will be distributed nationally in wellbeing centers, dispensaries, Spas, health food stores, Vitamin Shops, health care provider’s offices, online and through distributors.
To request further information about ProMED, please email info@promedcbd.com, or visit our website at https://promedcbd.com or on FB and Instagram @promedcbd, and Twitter @promedbio.
About Apotheca Biosciences Inc.
Apotheca Biosciences, a biopharmaceutical company, through its divisions, engages in 1) the discovery, development, and commercialization of therapies for the treatment of opioid addiction, sleep disorder, PTSD. Alzheimer's and inflammatory diseases worldwide, 2) develops and manufactures medical devices for precise dosing, and 3) direct to business and consumer CBD enhanced supplements, formulations and cosmetics. The pipeline of products includes, transdermal, sublingual, digestive technologies and medical devices for precise and controlled dosing of cannabinoids. Products such as CannaDERME, a transdermal technology using nano-emulsion for fast absorption of cannabinoid compounds for the general pain market.
To request further information about Apotheca, please email info@apothecabio.com, or visit its website at http://www.apothecabiosciences.com/, or visit it on FB @apotheca and Twitter @apotheca
Forward-Looking Statements
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Attachment